典型文献
CAR T cells redirected against tumor-specific antigen glycoforms:can low-sugar antigens guarantee a sweet success?
文献摘要:
Immune-based therapies have experienced a pronounced breakthrough in the past decades as they acquired multiple US Food and Drug Administration(FDA)approvals for various indications.To date,six chimeric antigen receptor T cell(CAR-T)therapies have been permitted for the treatment of certain patients with relapsed/refractory hematologic malignancies.However,several clinical trials of solid tumor CAR-T therapies were prematurely terminated,or they reported life-threatening treatment-related damages to healthy tissues.The simultaneous expression of target antigens by healthy organs and tumor cells is partly responsible for such toxicities.Alongside targeting tumor-specific antigens,targeting the aberrantly glycosylated glycoforms of tumor-associated antigens can also minimize the off-tumor effects of CAR-T therapies.Tn,T,and sialyl-Tn antigens have been reported to be involved in tumor progression and metastasis,and their expression results from the dysregulation of a series of glycosyltransferases and the endoplasmic reticulum protein chaperone,Cosmc.Moreover,these glycoforms have been associated with various types of cancers,including prostate,breast,colon,gastric,and lung cancers.Here,we discuss how underglycosylated antigens emerge and then detail the latest advances in the development of CAR-T-based immunotherapies that target some of such antigens.
文献关键词:
中图分类号:
作者姓名:
Pooria Safarzadeh Kozani;Pouya Safarzadeh Kozani;Fatemeh Rahbarizadeh
作者机构:
Department of Medical Biotechnology,Faculty of Medical Sciences,Tarbiat Modares University,Tehran,P.O.Box 14115/111,Iran;Department of Medical Biotechnology,Faculty of Paramedicine,Guilan University of Medical Sciences,Rasht,P.O.Box 44771/66595,Iran;Research and Development Center of Biotechnology,Tarbiat Modares University,Tehran,P.O.Box 14115/111,Iran
文献出处:
引用格式:
[1]Pooria Safarzadeh Kozani;Pouya Safarzadeh Kozani;Fatemeh Rahbarizadeh-.CAR T cells redirected against tumor-specific antigen glycoforms:can low-sugar antigens guarantee a sweet success?)[J].医学前沿,2022(03):322-338
A类:
glycoforms,Alongside,sialyl,Cosmc,underglycosylated
B类:
CAR,cells,redirected,against,tumor,specific,low,sugar,antigens,guarantee,sweet,success,Immune,have,experienced,pronounced,breakthrough,past,decades,they,acquired,multiple,US,Food,Drug,Administration,FDA,approvals,various,indications,To,date,six,chimeric,receptor,been,permitted,treatment,certain,patients,relapsed,refractory,hematologic,malignancies,However,several,clinical,trials,solid,were,prematurely,terminated,reported,life,threatening,related,damages,healthy,tissues,simultaneous,expression,by,organs,partly,responsible,such,toxicities,targeting,aberrantly,associated,also,minimize,off,effects,Tn,involved,progression,metastasis,their,results,from,dysregulation,series,glycosyltransferases,endoplasmic,reticulum,protein,chaperone,Moreover,these,types,cancers,including,prostate,breast,colon,gastric,lung,Here,discuss,how,emerge,then,detail,latest,advances,development,immunotherapies,that,some
AB值:
0.596422
相似文献
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。